RxDoctor Payments Data

Michael Appelblatt, DO

Family Medicine · Jupiter, FLNPI 1013332816

Payments from drug & device makers

$3,714in general payments, 2019–2025

Across 172 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$863
  • Novo Nordisk$435
  • Pfizer$433
  • Boehringer Ingelheim$390
  • GSK$226
  • Amgen$168
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,69399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,714 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$78,769
Medicare patients
315
Services billed
1,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$54,260
JardianceEmpagliflozin26$33,206
XareltoRivaroxaban20$28,675
JanuviaSitagliptin Phosphate20$22,702
JanumetSitagliptin Phos/Metformin Hcl15$21,832
ProliaDenosumab11$18,749
VascepaIcosapent Ethyl23$14,676
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,002
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$8,749
Atorvastatin Calcium760$5,908
SynthroidLevothyroxine Sodium44$4,814
TresibaInsulin Degludec11$4,517
Levothyroxine Sodium458$4,057
Rosuvastatin Calcium399$3,224
Amlodipine Besylate497$2,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$433$54,26044 claims
MerckJanuvia, Janumet$66$44,53435 claims
Boehringer IngelheimJardiance$390$33,20626 claims
AmgenProlia$168$18,74911 claims
GSKTrelegy Ellipta$226$12,00212 claims
Novo NordiskTresiba$435$4,51711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$4,057458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →